Biotech Values

[socaljewel]

You wrote: "Neovascularisation is a cascade effect where VEGF play a major role and is the target for pharmacological intervention.
Anti-VEGF therapies effectively block neovascularisation on nuumerous studies, but none of these drugs have any effect on mature retinal vessels. Most of these anti-angiogenic drugs currently tested are effective in preventing the development rather than regression of already established vessels."

So the test - looking at improvement in vision is really not appropriate for Macugen and Lucentis.

Let me congraduate you on your thorough research into all the therapies for AMD and how well you communicated your knowledge for us on this board. May I ask what profession you are in? What other drugs are you excited about?